Company news
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news
Every Sarepta Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 4
Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development
November 17, 2021
Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors
November 17, 2021
Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments
November 3, 2021
Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021
October 27, 2021
Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
October 13, 2021
Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
October 12, 2021
Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quar-ter Ended September 30, 2021
October 12, 2021
Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
October 11, 2021
Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio
October 4, 2021
Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
October 4, 2021
Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA
September 27, 2021
Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
September 14, 2021
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
September 7, 2021
Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
August 4, 2021
Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments
August 4, 2021
Sarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021
July 28, 2021
Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial Process Material
May 18, 2021
Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
May 17, 2021
Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
May 5, 2021
Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
May 3, 2021
Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
April 30, 2021
Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021
April 28, 2021
Sarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
April 26, 2021
Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
March 23, 2021
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
March 18, 2021
Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
March 15, 2021
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
March 1, 2021
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
February 25, 2021
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021
February 22, 2021
Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition
February 4, 2021
Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
January 13, 2021
Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 8, 2021
Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
January 7, 2021
Sarepta Therapeutics Announces Executive Management Changes
December 14, 2020
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
December 7, 2020
Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
December 4, 2020
Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
November 25, 2020
Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020
November 20, 2020
Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
November 5, 2020
Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
November 5, 2020
Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
November 2, 2020
Sarepta Therapeutics to Announce Third Quarter 2020 Financial Results and Recent Corporate Developments on November 5, 2020
October 29, 2020
Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
September 28, 2020
Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration
September 28, 2020
Long-term functional data from Sarepta Therapeutics’ Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World Muscle Society
September 14, 2020
Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
September 9, 2020
Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
August 25, 2020
Sarepta Therapeutics and University of Florida Announce Collaboration to Accelerate the Discovery and Development of Therapies for Rare Genetic Diseases
August 11, 2020
Sarepta Therapeutics Announces Second Quarter 2020 Financial Results and Recent Corporate Developments
August 5, 2020
Sarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020
July 29, 2020